Guidelines for the detection and treatment of liver metastases of colorectal cancer

Clinical and Translational Oncology

Volumn 9, Issue 11, 2007, Pages 723-730

  Abad, A ^a   Figueras, J ^b   Valls, C ^c   Carrato, A ^d   Pardo, F ^e   Diaz Rubio E ^f   Aranda, E ^g  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b HOSPITAL JOSEP TRUETA   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^e UNIVERSITY CLINIC OF NAVARRA   (Spain)

^f HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^g HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

Colorectal cancer; Liver metastases; Neoadjuvant chemotherapy; Surgical treatment

Indexed keywords

BEVACIZUMAB; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; FLUORODEOXYGLUCOSE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MANGAFODIPIR; OXALIPLATIN; SUPERPARAMAGNETIC IRON OXIDE; ANTINEOPLASTIC AGENT;

CANCER ADJUVANT THERAPY; CANCER RELAPSE; CANCER SURGERY; CLINICAL ASSESSMENT; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; ECHOGRAPHY; FATTY LIVER; FOLLOW UP; HEMANGIOMA; HUMAN; LIVER METASTASIS; LIVER RESECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; REVIEW; SIGMOIDOSCOPY; SURVIVAL TIME; TREATMENT INDICATION; COLORECTAL TUMOR; LIVER TUMOR; METASTASIS; PATHOLOGY;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; PRACTICE GUIDELINES AS TOPIC;

EID: 39749193591     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-007-0129-x     Document Type: Review

References (38)

1. Wooldridge JE, Shahab N, Doll DC (2003) Introduction: Post-treatment surveillance for potentially curable malignancies. Semin Oncol 30:337
2. Figueredo A, Rumble RB, Maroun J et al (2003) Follow-up of patients with curatively resected colorectal cancer: A practice guideline. BMC Cancer 3:26
3. (2001) ESMO minimum clinical recommendations for diagnosis, adjuvant treatment and follow-up of colon cancer. Ann Oncol 12:1053-1054
4. (2003) NCCN colon cancer clinical practice guidelines in oncology. J Natl Compr Cancer Network 1:40-53
5. Desch CE, Benson AB III, Somerfield MR et al (2005) Colorectal cancer surveillance: 2005 Update of an American Society of Clinical Oncology Practice Guideline. J Clin Oncol 23:8512-8519
6. Rodriguez-Moranta F, Saló J, Arcusa A et al (2006) Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: A prospective multicenter randomized controlled trial. J Clin Oncol 24:386-393
7. Valls C, Andía E, Sánchez A et al (2001) Helical CT in liver metastases from colorectal cancer: Preoperative detection and assessment of resectability. Radiology 218:55-60
8. Van Leuveen MS, Noordzij J, Feldberg MAM et al (1996) Focal liver lesions: Characterization with triphasic spiral CT. Radiology 201:327-336
9. Schwartz LH, Gandras EJ, Colangelo SM et al (1999) Prevalence and importance of small hepatic lesions found at CT in patients with cancer. Radiology 210:71-74
10. Ward J, Naik KS, Guthrie JA et al (1999) Hepatic lesion detection: comparison of MR imaging after the administration of superparamagnetic iron oxide with dual-phase CT by using alternative-free response receiver operating characteristic analysis. Radiology 210:459-466
11. Mori K, Takahashi N, Hiratsuka M et al (2006) Detection of hepatic metastases using ferucarbotran-enhanced MR imaging: Feasibility and diagnostic accuracy of three-dimensional sensitivity-encoding water-excitation multishot echo-planar sequence (3D-SWEEP). J Magn Reson Imaging 24:1110-1116
12. Bipat S, van Leeuwen MS, Comans EF et al (2005) Colorectal liver metastases: CT, MR imaging, and PET for diagnosis-meta-analysis. Radiology 237:123-131
13. Truant S, Huglo D, Hebbar M et al (2005) Prospective evaluation of the impact of [18F]fluoro-2-deoxy-D-glucose positron emission tomography of resectable colorectal liver metastases. Br J Surg 92:362-369
14. Scheele J, Stang R, Altendorf-Hofmann A (1995) Resection of colorectal liver metastases. World J Surg 19:59-71
15. Figueras J, Valls C, Rafecas A et al (2001) Resection rate and effect of postoperative chemotherapy on survival after surgery for colorectal liver metastases. Br J Surg 88:980-985
16. Figueras J, Torras J, Martí-Ragué J et al (2004) Resección quirúrgica de las metastasis hepáticas de carcinoma colorectal. Tratamiento de las recidivas. Cirugía Española 76:292-299
17. Fong Y, Fortner J, Sun RL et al (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer. Analysis of 1001 consecutive cases. Ann Surg 230:309-321
18. Nordlinger B, Guiget M, Vaillant JC et al (1996) Surgical resection of colorectal carcinoma metastases to the liver: A prognostic scoring system to improve case selection. Cancer 771: 1254-1262
19. Iwatsuki S, Dvorchik I, Madariaga JR et al (1999) Hepatic resection for metastatic colorectal adenocarcinoma. A proposal of a prognostic scoring system. J Am Coll Surg 189:291-299
20. Adam R, Pascal G, Castaing D et al (2004) Tumor progression while on chemotherapy. A contraindication to liver resection for multiple colorectal metastases. Ann Surg 240:1052-1064
21. Livraghi T, Solbiati L, Meloni F et al (2003) Percutaneous radiofrequency ablation of liver metastases in potential candidates for resection. The "test-of-time" approach. Cancer 97:3027-3035
22. De Baere T, Elias D, Dromain C et al (2000) Radiofrequency ablation of 100 hepatic metastases with a mean follow-up of more than a year. AJR Am J Roentgenol 175:1619-1625
23. Abdalla EK, Vauthey JN, Ellis LM et al (2004) Recurrence and outcomes following hepatic resection, radiofrequency ablation and combined resection/ablation for colorectal metastases. Ann Surg 239:818-827
24. Adam R, Avisar E, Ariche A et al (2001) Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 8:347-353
25. Adam R (2003) Chemotherapy and surgery: New perspectives on the treatment of unresectable liver metastases. Ann Oncol 14[Suppl 2]:iI13-ii16
26. Folprecht G, Grothey A, Alberts S et al (2005) Neoadjuvant treatment of unresectable colorectal liver metastases: Correlation between tumour response and resection rates. Ann Oncol 16: 1311-1319
27. Giacchetti S, Itzhaki M, Gruia G et al (1999) Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 10:663-669
28. Alberts SR, Horvath WL, Sternfeld WC et al (2005) Oxaliplatin, 5-fluorouracil, and leucovorin (FOLFOX4) for patients with unresectable liver-only metastases from colorectal cancer: A North Central Cancer Treatment Group (NCCTG) phase II study. J Clin Oncol 23:9243-9249
29. Pozzo C, Basso M, Cassano A et al (2004) Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol 15:933-939
30. Abad A, Massuti B, Antön A et al (2007) Colorectal cancer metastasis resectability after treatment with the combination of oxaliplatin, irinotecan and 5-fluorouracil. Final results of a phase II study. Acta Oncologica. 2007. In press
31. De Gramont A, Figer A, Seymur M et al (2000) Leucovorin and fluoracil with or without oxaliplatin as fist line treatment for advanced colorectal cancer. J Clin Oncol 18:2938-2947
32. Tournigand C, Louvet C, Quinaux E et al (2001) FOLFIRI followed by FOLFOX versus FOLFOX followed by FOLFIRI in metastatic colorectal cancer (MCRC): Final results of a Phase III study. Proc Am Soc Clin Oncol 20:124a (abst 494)
33. Dçiaz Rubio E, Tabernero J, Van Cutsem E et al (2005) Cetuximab in combination with oxaliplatin/5-fluorouracil/folinic acid (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal cancer: An international phase II study. J Clin Oncol 23[suppl; abstr 3535]:254
34. Vauthey JN, Pawlik TM, Ribero D (2006) Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 24:2065-2072
35. Ellis LM, Curley SA, Grothey A (2005) Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. J Clin Oncol 23:4853-4855
36. Kemeny N (2006) Management of liver metastases from colorectal cancer. Oncology (Huntingt) 20:1161-1176, 1179
37. Portier G, Elias D, Bouche O et al (2006) Multicenter randomized trial of adjuvant Fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 24:4976-4982
38. Sperti E, Faggiuolo R, Gerbino A et al (2006) Outcome of metastatic colorectal cancer: Analysis of a consecutive series of 229 patients. The impact of a multidisciplinary approach. Dis Colon Rectum 49:1596-1601